Pablo Tebas, MD
Professor of Medicine (Infectious Diseases) at the Hospital of the University of Pennsylvania
Attending Physician, Hospital of the University of Pennsylvania
Director & Principal Investigator, AIDS Clinical Trial Unit (ACTU) research site, University of Pennsylvania
Investigator of the Vaccine Trials Network, University of Pennsylvania
Department: Medicine
Contact information
Academic Address: 502 Johnson Pavilion
Clinical Office: 4 Perelman Center for Advanced Medicine, 3600 Civic Center Boulevard
Philadelphia, PA 19104
Clinical Office: 4 Perelman Center for Advanced Medicine, 3600 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-349-8092
Fax: 215-349-8011
Fax: 215-349-8011
Publications
Education:
MD
Universidad Autónoma de Madrid, Spain, 1985.
Permanent linkMD
Universidad Autónoma de Madrid, Spain, 1985.
Description of Research Expertise
My research interests center around the study of the complications of HIV and its treatment, and currently in the evaluation of strategies for the cure of HIV infection.I am the director and the PI of the AIDS clinical trial unit of the University of Pennsylvania.
I am one of the founding members of the HIV Reservoirs and Viral Eradication (Cure) Transformative Science Group (TSG) of the AIDS clinical trial group. In addition to my ACTG work, I am involved (as PI of the clinical project) in several early phase trials of new compounds developed in conjunction with the NIH in several IPCP grants, including a Phase I study evaluating the antiviral activity of aprepitant (an NK-1R antagonist that down-regulates the expression of CCR5), a phase I study evaluating the immunogenicity of a therapeutic DNA vaccine administered by intramuscular electroporation in collaboration with David Weiner and several gene therapy studies evaluating the therapeutic use of lentiviral vectors in the management of HIV infection (including the use of VIRxSYS 496 –antisense approach-, the first in humans Sangamo’s zinc finger nuclease for CCR5 edition, in collaboration with Dr. Carl June.
Description of Clinical Expertise
My clinical interest focus on the treatment of HIV infection and associated infections like hepatitis C. I have also a particular interest in the clinical manifestations and treatment of atypical mycobacterial infections. I also attend every year in the general infectious disease service of the hospital of University of PennsylvaniaSelected Publications
Moskovljevic, M., Dragoni, F., Board, N. L., Wu, F., Lai, J., Zhang, H., White, J. R., Hoh, R., Lynn, K., Tebas, P., Mounzer, K., Deeks, S. G., Montaner, L. J., Siliciano, J. D., Siliciano, R. F., Simonetti, F. R.: Cognate antigen engagement induces HIV-1 expression in latently infected CD4(+) T cells from people on long-term antiretroviral therapy. Immunity November 2024.Gulick, R. M., Pau, A. K., Daar, E., Evans, L., Gandhi, R. T., Tebas, P., Ridzon, R., Masur, H., Lane, H. C., Nih Covid- Treatment Guidelines Panel, Adimora, A. A., Baker, J., Kreuziger, L. B., Bedimo, R., Belperio, P., Bhalla, A., Burgess, T., Campbell, D., Cantrill, S., Chew, K., Chiotos, K., Coopersmith, C., Davey, R., Dzierba, A., Eisnor, D., Eschenauer, G., Francis, J., Gallagher, J., Glidden, D., Goldenberg, N., Grund, B., Han, A., Hardy, E., Harrison, C., Henderson, L., Higgs, E., Hinkson, C., Hughes, B., Johnson, S., Keller, M., Kim, A., Knight, R., Kuriakose, S., Lennox, J., Lerner, A., Levy, M., Li, J., MacBrayne, C., Martin, G., Nadig, N., Nason, M., Patel, P., Pavia, A., Proschan, M., Schulert, G., Seam, N., Sheikh, V., Simpson, S., Singh, K., Swindells, S., Tien, P., Uyeki, T., Waghmare, A., Wolfe, C., Yazdany, J., Aberg, J.: National Institutes of Health COVID-19 Treatment Guidelines Panel: Perspectives and Lessons Learned. Ann Intern Med 177(11): 1547-1557, November 2024.
Pahus, M. H., Zheng, Y., Olefsky, M., Gunst, J. D., Tebas, P., Taiwo, B., Sogaard, O. S., Peluso, M. J., Lie, Y., Reeves, J. D., Petropoulos, C. J., Caskey, M., Bar, K. J.: Evaluation and real-world experience of a neutralization susceptibility screening assay for broadly neutralizing anti-HIV-1 antibodies. J Infect Dis October 2024.
Bhimraj, A., Falck-Ytter, Y., Kim, A. Y., Li, J. Z., Baden, L. R., Johnson, S., Shafer, R. W., Shoham, S., Tebas, P., Bedimo, R., Cheng, V. C., Chew, K. W., Chiotos, K., Daar, E. S., Dzierba, A. L., Glidden, D. V., Hardy, E. J., Martin, G. S., MacBrayne, C., Nadig, N., Nakamura, M. M., Shumaker, A. H., Tien, P., Loveless, J., Morgan, R. L., Gandhi, R. T.: 2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis. Clin Infect Dis October 2024.
Papasavvas, E., Lu, L., Fair, M., Oliva, I., Cassel, J., Majumdar, S., Mounzer, K., Kostman, J. R., Tebas, P., Bar-Or, A., Muthumani, K., Montaner, L. J.: Cloning and Functional Characterization of Novel Human Neutralizing Anti-IFN-alpha and Anti-IFN-beta Antibodies. J Immunol 213(6): 808-822, September 2024.
Lee, M. J., Eason, M., Castagna, A., Laura, G., De Scheerder, M. A., Riley, J., Tebas, P., Gunst, J., Sogaard, O., Florence, E., Kroon, E., De Souza, M., Mothe, B., Caskey, M., Fidler, S.: The impact of analytical treatment interruptions and trial interventions on time to viral re-suppression in people living with HIV restarting ART in cure-related clinical studies: a systematic review and meta-analysis. J Int AIDS Soc 27(8): e26349, August 2024.
Hamilton, K. W., Hua, E., Dutcher, L., Fernandez Lynch, H., Junker, P., Doucette, A. G., Werner, D., Kannel, E. Z., Civitello, T., Gabriel, P., Ahya, V. N., Jacobs, D. A., Garfall, A., Pratz, K., Degnan, K. O., Blumberg, E. A., Capozzi, D., Craig, E., Takach, P., Payne, A. S., Geara, A., Koenig, H., Holzman, L., Tebas, P.: Implementation of an Approach to Equitable Allocation of SARS-CoV-2 Monoclonal Antibodies for Preexposure Prophylaxis: Experience From a Single Medical Center. Open Forum Infect Dis 11(8): ofae388, July 2024.
Molina, J. M., Rizzardini, G., Orrell, C., Afani, A., Calmy, A., Oka, S., Hinestrosa, F., Kumar, P., Tebas, P., Walmsley, S., Grandhi, A., Klopfer, S., Gendrano, I., Eves, K., Correll, T. A., Fox, M. C., Kim, J.: Switch to fixed-dose doravirine (100 mg) with islatravir (0.75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial. Lancet HIV 11(6): e369-e379, June 2024.
Jacobson, J. M., Felber, B. K., Chen, H., Pavlakis, G. N., Mullins, J. I., De Rosa, S. C., Kuritzkes, D. R., Tomaras, G. D., Kinslow, J., Bao, Y., Olefsky, M., Rosati, M., Bear, J., Heptinstall, J. R., Zhang, L., Sawant, S., Hannaman, D., Laird, G. M., Cyktor, J. C., Heath, S. L., Collier, A. C., Koletar, S. L., Taiwo, B. O., Tebas, P., Wohl, D. A., Belaunzaran-Zamudio, P. F., McElrath, M. J., Landay, A. L., Actg Study Team: The immunogenicity of an HIV-1 Gag conserved element DNA vaccine in people with HIV and receiving antiretroviral therapy. AIDS 38(7): 963-973, June 2024.
Papasavvas, E., Lu, L., Fair, M., Oliva, I., Cassel, J., Majumdar, S., Mounzer, K., Kostman, J. R., Tebas, P., Bar-Or, A., Muthumani, K., Montaner, L. J.: Cloning and functional characterization of novel human neutralizing anti-interferon-alpha and anti-interferon-beta antibodies. bioRxiv May 2024.